Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment.

Sy A, Srinivasan M, Mascarenhas J, Lalitha P, Rajaraman R, Ravindran M, Oldenburg CE, Ray KJ, Glidden D, Zegans ME, McLeod SD, Lietman TM, Acharya NR.

Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):267-72. doi: 10.1167/iovs.11-7840.

2.

Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).

Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, Ray KJ, Hong KC, Oldenburg CE, Lee SM, Zegans ME, McLeod SD, Lietman TM, Acharya NR; Steroids for Corneal Ulcers Trial Group.

Arch Ophthalmol. 2012 Feb;130(2):143-50. doi: 10.1001/archophthalmol.2011.315. Epub 2011 Oct 10.

3.

The steroids for corneal ulcers trial: study design and baseline characteristics.

Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, Ray KJ, Hong KC, Oldenburg CE, Lee SM, Zegans ME, McLeod SD, Lietman TM, Acharya NR; Steroids for Corneal Ulcers Trial Group.

Arch Ophthalmol. 2012 Feb;130(2):151-7. doi: 10.1001/archophthalmol.2011.303. Epub 2011 Oct 10.

4.

Community opinions in the management of corneal ulcers and ophthalmic antibiotics: a survey of 4 states.

Hsu HY, Nacke R, Song JC, Yoo SH, Alfonso EC, Israel HA.

Eye Contact Lens. 2010 Jul;36(4):195-200.

PMID:
20626115
5.

Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis.

Sueke H, Kaye S, Neal T, Murphy C, Hall A, Whittaker D, Tuft S, Parry C.

Invest Ophthalmol Vis Sci. 2010 May;51(5):2519-24. doi: 10.1167/iovs.09-4638. Epub 2009 Dec 17.

PMID:
20019362
6.

Bacterial susceptibility to topical antimicrobials and clinical outcome in bacterial keratitis.

Kaye S, Tuft S, Neal T, Tole D, Leeming J, Figueiredo F, Armstrong M, McDonnell P, Tullo A, Parry C.

Invest Ophthalmol Vis Sci. 2010 Jan;51(1):362-8. doi: 10.1167/iovs.09-3933. Epub 2009 Aug 13.

PMID:
19684005
7.

Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty.

Holland EJ, Lane SS, Kim T, Raizman M, Dunn S.

Cornea. 2008 Apr;27(3):314-9. doi: 10.1097/ICO.0b013e3181608561.

PMID:
18362660
8.

Does in vitro susceptibility predict clinical outcome in bacterial keratitis?

Chen A, Prajna L, Srinivasan M, Mahalakshmi R, Whitcher JP, McLeod S, Lietman TM, Acharya NR.

Am J Ophthalmol. 2008 Mar;145(3):409-412. doi: 10.1016/j.ajo.2007.11.004. Epub 2008 Jan 22.

9.

Microbial keratitis in South India: influence of risk factors, climate, and geographical variation.

Bharathi MJ, Ramakrishnan R, Meenakshi R, Padmavathy S, Shivakumar C, Srinivasan M.

Ophthalmic Epidemiol. 2007 Mar-Apr;14(2):61-9.

PMID:
17464852
10.

In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.

Oliveira AD, D'Azevedo PA, Francisco W.

Cornea. 2007 Feb;26(2):194-8.

PMID:
17251812
11.

Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor.

Solomon R, Donnenfeld ED, Perry HD, Snyder RW, Nedrud C, Stein J, Bloom A.

Ophthalmology. 2005 Mar;112(3):466-9.

PMID:
15745775
12.

Global data on visual impairment in the year 2002.

Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP.

Bull World Health Organ. 2004 Nov;82(11):844-51. Epub 2004 Dec 14.

13.

Trends in the etiology of infectious corneal ulcers at the F. I. Proctor Foundation.

Varaprasathan G, Miller K, Lietman T, Whitcher JP, Cevallos V, Okumoto M, Margolis TP, Yinghui M, Cunningham ET Jr.

Cornea. 2004 May;23(4):360-4.

PMID:
15097130
14.

Evaluation and prediction of fluoroquinolone pharmacodynamics in bacterial keratitis.

Wilhelmus KR.

J Ocul Pharmacol Ther. 2003 Oct;19(5):493-9.

PMID:
14583139
15.

Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis.

Wilhelmus KR, Abshire RL, Schlech BA.

Arch Ophthalmol. 2003 Sep;121(9):1229-33.

PMID:
12963604
16.

An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.

Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, Baddour LM, Luna CM, Snydman DR, Ip M, Ko WC, Chedid MB, Andremont A, Klugman KP; International Pneumococcal Study Group.

Clin Infect Dis. 2003 Jul 15;37(2):230-7. Epub 2003 Jul 7.

PMID:
12856216
17.

Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases.

Bourcier T, Thomas F, Borderie V, Chaumeil C, Laroche L.

Br J Ophthalmol. 2003 Jul;87(7):834-8.

18.
19.

Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis.

Leck AK, Thomas PA, Hagan M, Kaliamurthy J, Ackuaku E, John M, Newman MJ, Codjoe FS, Opintan JA, Kalavathy CM, Essuman V, Jesudasan CA, Johnson GJ.

Br J Ophthalmol. 2002 Nov;86(11):1211-5.

20.

Has antifungal susceptibility testing come of age?

Rex JH, Pfaller MA.

Clin Infect Dis. 2002 Oct 15;35(8):982-9. Epub 2002 Sep 24.

PMID:
12355386

Supplemental Content

Support Center